Anti-interleukin-5 therapy in severe asthma
Authors:
- Gilles GarciaGGGilles Garcia
- Camille TailléCTCamille Taillé
- Pierantonio LavenezianaPLPierantonio Laveneziana
- Arnaud BourdinABArnaud Bourdin
- Pascal ChanezPCPascal Chanez
- Marc HumbertMHMarc Humbert
Open Access
- 30 August 2013
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 22 (129) , 251-257
Abstract
Asthma is a chronic inflammatory disorder of the airways that leads to acute symptoms, exacerbations and sometimes, for a small part of the asthmatic population, fatal or near-fatal exacerbations. This as yet significant minority of individuals present with severe asthma and have persisting daily symptoms, and exacerbations despite compliance with high doses of inhaled steroids and additional treatment. For more than a decade, the pharmacological management of patients with severe asthma has focused on evaluating specific cytokines. The rationale of this approach is based on the distinguished key role played by eosinophils in the asthma inflammatory processes. Eosinophils are recruited from the circulation to airways where they cause airway damageviadifferent mechanisms. Eosinophils are regulated in terms of their recruitment, activation, growth, differentiation and survival by interleukin (IL)-5. Abundant data fromin vitroexperiments, animal models and clinical trials has confirmed that IL-5 inhibition may be an effective approach for the treatment of asthma, especially severe asthma. Interfering with eosinophil function or reducing their numbers has been one of the most important goals of therapeutic monoclonal antibodies, which target cytokine receptor interactions in asthma, particularly IL-5. This review will consider new treatments options for severe asthma, particularly those targeting IL-5, that have already been evaluated in clinical trials in asthmatic patients.Keywords
This publication has 150 references indexed in Scilit:
- Novel targeted therapies for eosinophilic disordersJournal of Allergy and Clinical Immunology, 2012
- Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthmaJournal of Allergy and Clinical Immunology, 2010
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity functionJournal of Allergy and Clinical Immunology, 2010
- Tissue and BAL Based Biomarkers in AsthmaImmunology and Allergy Clinics of North America, 2007
- Severe asthma in adults: What are the important questions?Journal of Allergy and Clinical Immunology, 2007
- Eosinophil trafficking in allergy and asthmaJournal of Allergy and Clinical Immunology, 2007
- Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramJournal of Allergy and Clinical Immunology, 2007
- Anti-Interleukin-5 Monoclonal AntibodiesAmerican Journal of Respiratory Medicine, 2003
- Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic responseThe Lancet, 2000
- Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthmaJournal of Allergy and Clinical Immunology, 1993